Mounjaro Kwikpen (Tirzepatide)

Tirzepatide, the active ingredient in Mounjaro Kwikpen, is a dual GIP and GLP‑1 receptor agonist presented as a prefilled pen for subcutaneous use. It treats type 2 diabetes mellitus in adults and is approved in the European Union. The medication improves glycaemic control by enhancing insulin secretion and reducing glucagon release in a glucose‑dependent manner, typically administered once weekly.

GNH USA supplies Mounjaro Kwikpen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance.

Mounjaro Kwikpen, a dual GIP and GLP‑1 receptor agonist, is indicated for the treatment of type 2 diabetes mellitus in adult patients, helping to achieve target blood glucose levels as part of a comprehensive management plan that includes diet, exercise, and other antidiabetic therapies. - Type 2 diabetes mellitus: improves glycaemic control, lowers HbA1c, and reduces fasting plasma glucose when used with diet and exercise. - Type 2 diabetes mellitus (add‑on therapy): provides additional HbA1c reduction when combined with metformin or other oral agents.

Tirzepatide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Vomiting - Diarrhea - Decreased appetite

Serious or Rare Side Effects: - Pancreatitis - Severe allergic reaction (anaphylaxis) - Acute kidney injury

When prescribing tirzepatide, clinicians should consider several safety measures. - Monitor blood glucose: adjust concomitant antidiabetic agents to avoid hypoglycaemia. - Assess renal function: use with caution in patients with impaired kidney function. - Review history of pancreatitis: avoid in individuals with prior episodes. - Contraindicated in pregnancy until safety is established: avoid use in pregnant women. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Tirzepatide can interact with other medicines, requiring attention to dosing and monitoring.

Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of severe hypoglycaemia. - Other GLP‑1 receptor agonists: additive gastrointestinal effects.

Moderate Interactions (Monitor Closely): - Warfarin: monitor INR for potential anticoagulant effect changes. - Diuretics: watch for alterations in fluid balance and renal function. - Oral contraceptives: possible reduced efficacy, consider additional contraception.